| | | |
D-allose + Platinum
|
D-allose + 20 μM SB202190 (mM)
|
D-allose + 20 μM SB202190 + Platinum
|
|---|
|
Cell line
|
D-allose (mM)
|
Platinum (μM)
|
D-allose (mM)
|
Platinum (μM)
|
CI at IC50
|
D-allose (mM)
|
Platinum (μM)
|
|---|
|
MIA PaCa-2
|
53.25
|
3.37
|
4.16
|
0.95
|
0.696
|
3.18
|
1.98
|
0.99
|
|
BxPC-3
|
>100
|
28.13
|
43.3
|
21.65
|
0.787
|
4.09
|
8.75
|
4.38
|
|
ASPC-1
|
>100
|
>50
|
>100
|
>50
|
n/c
|
74.11
|
>100
|
>50
|
|
OVCAR-3
|
>100
|
6.93
|
15.84
|
7.92
|
1.171
|
>100
|
51.7
|
25.85
|
|
HEY
|
>100
|
32.90
|
52.68
|
26.34
|
1.002
|
94.17
|
53.01
|
26.5
|
|
SK-OV-3
|
>100
|
11.53
|
18.55
|
9.27
|
0.857
|
10.82
|
9.74
|
4.87
|
- IC50 values represent the level of drug that inhibited cell growth by 50% following 48 hours of treatment. Combination index (CI) values are defined as: <0.1 = very strong synergy, 0.1-0.3 = strong synergism, 0.3-0.7 = synergism, 0.7 – 0.85 = moderate synergism, 0.85-0.9 = slight synergism, 0.9-1.1 = nearly additive, 1.1-1.45 slight to moderate antagonism.
